sumanirole
Small moleculeexperimental
Sumanirole (PNU-95,666) is a highly selective D2 receptor full agonist, the first of its kind to be discovered. It was developed for the treatment of Parkinson's disease and restless leg syndrome. While it has never been approved for medical use it is a highly valuable tool compound for basic research to identify neurobiological mechanisms that are based on a dopamine D2-linked (vs. D1-, D3-, D4-, and D5-linked) mechanism of action. — Wikipedia
Clinical trial activity
3 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
3
Phase 3
3
Phase 4
0
Earliest trial started Aug 1, 2000 (NCT00036205)
Timeline
2000s
- Jan 1, 2000
Earliest Phase 3 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Dopamine D2 receptorAGONIST
DRD2 agonist
Chemistry & pharmacology
Loading structure…
SMILES
CN[C@@H]1Cc2cccc3[nH]c(=O)n(c23)C1- Mol. weight
- 203.25 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- Yes
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaSumanirole ↗
- ChEMBLCHEMBL419792 ↗
Also known as
- 5,6-dihydro-5-(methylamino)-4h-imidazo(4,5,1ij)-quinolin-2(1h)-one (z)-2-butenedioate
- pnu-95666
- pnu-95666e
- pnu-95666e
- sumanirole
- sumanirole
- sumanirole
- sumanirole
- u 95666e
- u-95666e
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00058838 | Phase 3 | Apr 1, 2003 | Pfizer |
| NCT00036218 | Phase 3 | Dec 1, 2001 | Pfizer |
| NCT00036205 | Phase 3 | Aug 1, 2000 | Pfizer |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Pfizer | For profit | 3 | 3 | 1 | 2000 |
1 organizations
Page 1 / 1